Profile data is unavailable for this security.
About the company
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.
- Revenue in USD (TTM)0.00
- Net income in USD-9.36m
- Incorporated2005
- Employees7.00
- LocationNanoViricides Inc1 Controls DriveSHELTON 06484United StatesUSA
- Phone+1 (203) 937-6137
- Fax+1 (203) 859-5095
- Websitehttp://www.nanoviricides.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coeptis Therapeutics Holdings Inc | 0.00 | -21.27m | 13.34m | 5.00 | -- | 3.03 | -- | -- | -0.8922 | -0.8922 | 0.00 | 0.1221 | 0.00 | -- | -- | 0.00 | -266.05 | -36.90 | -392.90 | -37.81 | -- | -- | -- | -- | -- | -- | 0.2068 | -- | -- | -- | 43.40 | -- | -- | -- |
| Actavia Life Sciences Inc | 0.00 | -4.44m | 13.35m | 1.00 | -- | -- | -- | -- | -0.0074 | -0.0074 | 0.00 | -0.0027 | 0.00 | -- | -- | 0.00 | -10,235.89 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -21.20 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Dominari Holdings Inc | 2.04m | -22.88m | 13.35m | 26.00 | -- | 0.2523 | -- | 6.55 | -4.44 | -4.44 | 0.3899 | 8.92 | 0.0305 | -- | 0.3829 | 78,423.08 | -34.20 | -26.82 | -35.10 | -27.45 | -- | -- | -1,122.22 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 13.47m | 233.00 | 0.0904 | 0.0014 | 3.49 | 0.1903 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Nexgel Inc | 4.09m | -3.16m | 13.89m | 19.00 | -- | 2.73 | -- | 3.40 | -0.5566 | -0.5566 | 0.7212 | 0.818 | 0.4027 | 3.81 | 9.57 | 215,263.20 | -31.39 | -44.61 | -38.80 | -56.19 | 15.16 | 5.02 | -77.95 | -180.98 | 1.46 | -- | 0.1396 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 42.81m | -24.54m | 13.90m | 46.00 | -- | 0.5195 | -- | 0.3247 | -22.94 | -22.94 | 38.03 | 21.64 | 0.6382 | -- | 13.42 | 930,652.20 | -36.58 | -28.41 | -57.30 | -39.69 | -- | -- | -57.33 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| NanoViricides Inc | 0.00 | -9.36m | 14.13m | 7.00 | -- | 1.22 | -- | -- | -0.8004 | -0.8004 | 0.00 | 0.9828 | 0.00 | -- | -- | 0.00 | -55.47 | -43.54 | -57.90 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -13.04m | 14.25m | 12.00 | -- | 0.6843 | -- | -- | -2.98 | -2.98 | 0.00 | 0.7929 | 0.00 | -- | -- | 0.00 | -77.27 | -70.52 | -91.06 | -81.86 | -- | -- | -- | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -10.74m | 14.38m | 22.00 | -- | 2.60 | -- | -- | -1.08 | -1.08 | 0.00 | 0.3845 | 0.00 | -- | -- | 0.00 | -120.24 | -53.28 | -178.87 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Tonix Pharmaceuticals Holding Corp | 7.77m | -116.66m | 14.46m | 103.00 | -- | 0.095 | -- | 1.86 | -8.62 | -8.62 | 0.4572 | 1.80 | 0.0409 | -- | -- | 75,417.48 | -61.38 | -59.46 | -68.01 | -65.92 | 38.97 | -- | -1,501.78 | -5,126.73 | 1.81 | -- | 0.0779 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| GlucoTrack Inc | 0.00 | -7.10m | 14.58m | 6.00 | -- | 3.56 | -- | -- | -0.3394 | -0.3394 | 0.00 | 0.153 | 0.00 | -- | -- | 0.00 | -193.30 | -94.01 | -294.60 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.0578 | -- | -- | -- | -60.02 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.72m | 14.65m | 16.00 | -- | 2.47 | -- | -- | -2.60 | -2.60 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -79.13 | -- | -95.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 454.70k | 3.86% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 159.30k | 1.35% |
| Banque Lombard Odier & Cie SA (Investment Management)as of 31 Dec 2023 | 150.00k | 1.27% |
| Geode Capital Management LLCas of 31 Dec 2023 | 109.49k | 0.93% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 78.50k | 0.67% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 59.04k | 0.50% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 41.91k | 0.36% |
| City National Rochdale LLCas of 31 Dec 2023 | 30.54k | 0.26% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 29.66k | 0.25% |
| Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Dec 2023 | 21.20k | 0.18% |
